BPS 034
Alternative Names: BPDO-1603; BPS-034Latest Information Update: 24 Apr 2023
At a glance
- Originator Hyundai Pharmaceutical
- Class Antidementias; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Alzheimer's disease
Most Recent Events
- 14 Mar 2023 Hyundai Pharm completes a phase I trial for Alzheimer's disease (In volunteers) in South Korea (PO) (NCT05804279)
- 28 Dec 2022 Hyundai Pharm initiates a phase I trial for Alzheimer's disease (In volunteers) in South Korea (PO) (NCT05804279)
- 09 Dec 2022 BPS 034 still in phase-III development in Alzheimer's disease in South Korea (PO, Tablet) (Hyundai Pharmaceutical pipeline, December 2022)